Renchi Yang

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8972510/publications.pdf

Version: 2024-02-01

		331670	361022
95	1,715	21	35
papers	citations	h-index	g-index

96	96	96	1599
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Abnormality of CD4+CD25+regulatory T cells in idiopathic thrombocytopenic purpura. European Journal of Haematology, 2006, 78, 061213212227003-???.	2.2	199
2	Type 1 and type 2 T-cell profiles in idiopathic thrombocytopenic purpura. Haematologica, 2005, 90, 914-23.	3.5	129
3	A multicenter randomized controlled trial of recombinant human thrombopoietin treatment in patients with primary immune thrombocytopenia. International Journal of Hematology, 2012, 96, 222-228.	1.6	77
4	Prophylaxis vs. onâ€demand treatment with BAY 81â€8973, a fullâ€length plasma proteinâ€free recombinant factor VIII product: results from a randomized trial (LEOPOLD II). Journal of Thrombosis and Haemostasis, 2015, 13, 360-369.	3.8	74
5	Multicentre, randomised phase <scp>III</scp> study of the efficacy and safety of eltrombopag in Chinese patients with chronic immune thrombocytopenia. British Journal of Haematology, 2017, 176, 101-110.	2.5	55
6	BAFF and BAFF-R of peripheral blood and spleen mononuclear cells in idiopathic thrombocytopenic purpura. Autoimmunity, 2009, 42, 112-119.	2.6	41
7	Immunosuppressive function of mesenchymal stem cells from human umbilical cord matrix in immune thrombocytopenia patients. Thrombosis and Haemostasis, 2012, 107, 937-950.	3.4	37
8	Longâ€term results of splenectomy in adult chronic immune thrombocytopenia. European Journal of Haematology, 2017, 98, 235-241.	2.2	36
9	A multicenter, randomized phase III trial of hetrombopag: a novel thrombopoietin receptor agonist for the treatment of immune thrombocytopenia. Journal of Hematology and Oncology, 2021, 14, 37.	17.0	33
10	The Effect of Danazol in Primary Immune Thrombocytopenia. Clinical and Applied Thrombosis/Hemostasis, 2016, 22, 727-733.	1.7	31
11	Th1 (CXCL10) and Th2 (CCL2) chemokine expression in patients with immune thrombocytopenia. Human Immunology, 2010, 71, 586-591.	2.4	30
12	Splenectomy for Chronic Idiopathic Thrombocytopenic Purpura in Children: A Single Center Study in China. Acta Haematologica, 2006, 115, 39-45.	1.4	28
13	Rituximab treatment for chronic refractory idiopathic thrombocytopenic purpura. Critical Reviews in Oncology/Hematology, 2008, 65, 21-31.	4.4	28
14	Hemophilic Pseudotumor in Chinese Patients: A Retrospective Single-Centered Analysis of 14 Cases. Clinical and Applied Thrombosis/Hemostasis, 2011, 17, 279-282.	1.7	28
15	The defective bone marrow-derived mesenchymal stem cells in patients with chronic immune thrombocytopenia. Autoimmunity, 2014, 47, 519-529.	2.6	28
16	Outcome of CARE: a 6â€year national registry of acquired haemophilia A in China. British Journal of Haematology, 2019, 187, 653-665.	2.5	28
17	Healthâ€related quality of life and health status in persons with haemophilia A with inhibitors: A prospective, multicentre, nonâ€interventional study (NIS). Haemophilia, 2019, 25, 382-391.	2.1	28
18	Paediatric essential thrombocythaemia: clinical and molecular features, diagnosis and treatment. British Journal of Haematology, 2013, 163, 295-302.	2.5	25

#	Article	IF	Citations
19	Association of ABCB1 gene polymorphisms and haplotypes with therapeutic efficacy of glucocorticoids in Chinese patients with immune thrombocytopenia. Human Immunology, 2014, 75, 317-321.	2.4	25
20	External validation and clinical evaluation of the International Prognostic Score of Thrombosis for Essential Thrombocythemia (<scp>IPSET</scp>â€thrombosis) in a large cohort of <scp>C</scp>hinese patients. European Journal of Haematology, 2014, 92, 502-509.	2.2	24
21	Carbapenem-resistant Enterobacteriaceae in hematological patients: Outcome of patients with Carbapenem-resistant Enterobacteriaceae infection and risk factors for progression to infection after rectal colonization. International Journal of Antimicrobial Agents, 2019, 54, 527-529.	2.5	24
22	Prophylactic emicizumab for hemophilia A in the Asiaâ€Pacific region: A randomized study (HAVEN 5). Research and Practice in Thrombosis and Haemostasis, 2022, 6, e12670.	2.3	24
23	Meeting the challenges of haemophilia care and patient support in China and Brazil. Haemophilia, 2012, 18, 33-38.	2.1	23
24	Reduced expression of <scp>MIR</scp>409â€3p in primary immune thrombocytopenia. British Journal of Haematology, 2013, 161, 128-135.	2.5	23
25	Decreased IL-35 levels in patients with immune thrombocytopenia. Human Immunology, 2014, 75, 909-913.	2.4	21
26	Factor VIII gene mutations profile in 148 Chinese hemophilia A subjects. European Journal of Haematology, 2010, 85, 264-272.	2.2	20
27	Aberrant expression of long noncoding RNA TMEVPG1 in patients with primary immune thrombocytopenia. Autoimmunity, 2016, 49, 496-502.	2.6	20
28	Bleeding events and safety outcomes in persons with haemophilia A with inhibitors: A prospective, multiâ€centre, nonâ€interventional study. Haemophilia, 2018, 24, 921-929.	2.1	20
29	Haemophilia care in China: Achievements in the past decade. Haemophilia, 2020, 26, 759-767.	2.1	20
30	Angiogenesis in Hematologic Malignancies and Its Clinical Implications. International Journal of Hematology, 2002, 75, 246-256.	1.6	19
31	ReducedMIR130Ais involved in primary immune thrombocytopenia via targetingTGFB1andIL18. British Journal of Haematology, 2014, 166, 767-773.	2.5	19
32	Acquired Hemophilia A. Clinical and Applied Thrombosis/Hemostasis, 2015, 21, 35-40.	1.7	19
33	Interleukin 35 may contribute to the loss of immunological selfâ€tolerance in patients with primary immune thrombocytopenia. British Journal of Haematology, 2015, 169, 278-285.	2.5	19
34	Elevated Semaphorin 5A correlated with Th1 polarization in patients with chronic immune thrombocytopenia. Thrombosis Research, 2015, 136, 859-864.	1.7	19
35	Splenectomy for adult chronic idiopathic thrombocytopenic purpura: experience from a single center in China. European Journal of Haematology, 2005, 75, 424-429.	2.2	18
36	The expression of IFN-Î³, IL-4, Foxp3 and perforin genes are not correlated with DNA methylation status in patients with immune thrombocytopenic purpura. Platelets, 2010, 21, 137-143.	2.3	18

#	Article	IF	Citations
37	Evaluating the psychometric properties of the EQ-5D-5L and SF-6D among patients with haemophilia. European Journal of Health Economics, 2021, 22, 547-557.	2.8	18
38	Efficacy and safety of eltrombopag in Chinese patients with chronic immune thrombocytopenia: stage 2 results from a multicenter phase III study. Platelets, 2022, 33, 82-88.	2.3	17
39	Building a network for hemophilia care in China: 15 years of achievement for the Hemophilia Treatment Center Collaborative Network of China. Blood Advances, 2019, 3, 34-37.	5.2	16
40	Thrombopoietic growth factors in the treatment of immune thrombocytopenic purpura. Critical Reviews in Oncology/Hematology, 2011, 77, 172-183.	4.4	15
41	An overview of patients with haemophilia A in China: Epidemiology, disease severity and treatment strategies. Haemophilia, 2021, 27, e51-e59.	2.1	15
42	CD72 Polymorphism Associated with Child-Onset of Idiopathic Thrombocytopenic Purpura in Chinese Patients. Journal of Clinical Immunology, 2008, 28, 214-219.	3.8	14
43	The Efficacy of Recombinant FVIII Low-Dose Prophylaxis in Chinese Pediatric Patients With Severe Hemophilia A: A Retrospective Analysis From the ReCARE Study. Clinical and Applied Thrombosis/Hemostasis, 2017, 23, 851-858.	1.7	14
44	Role of bone marrowâ€derived mesenchymal stem cell defects in CD8⁺CD28^{â€“} suppressor Tâ€lymphocyte induction in patients with immune thrombocytopenia and associated mechanisms. British Journal of Haematology, 2020, 191, 852-862.	2.5	14
45	Different dosages of intravenous immunoglobulin (IVIg) in treating immune thrombocytopenia with long-term follow-up of three years: Results of a prospective study including 167 cases. Autoimmunity, 2016, 49, 50-57.	2.6	13
46	Upregulation of CD72 expression on CD19⁺CD27⁺ memory BÂcells by CD40L in primary immune thrombocytopenia. British Journal of Haematology, 2017, 178, 308-318.	2.5	13
47	Current and emerging treatments for immune thrombocytopenia. Expert Review of Hematology, 2019, 12, 723-732.	2.2	13
48	Efficacy of standard prophylaxis versus on-demand treatment with bayer's sucrose-formulated recombinant FVIII (rFVIII-FS) in Chinese children with severe hemophilia A. Pediatric Hematology and Oncology, 2017, 34, 146-156.	0.8	12
49	DNA Methylation and Primary Immune Thrombocytopenia. Seminars in Hematology, 2013, 50, S116-S126.	3.4	11
50	The polymorphisms of T cell-specific TBX21 gene may contribute to the susceptibility of chronic immune thrombocytopenia in Chinese population. Human Immunology, 2014, 75, 129-133.	2.4	11
51	The polymorphisms of tumor necrosis factor-induced protein 3 gene may contribute to the susceptibility of chronic primary immune thrombocytopenia in Chinese population. Platelets, 2016, 27, 26-31.	2.3	11
52	Abnormal Distribution and Function of Monocyte Subsets in Patients With Primary Immune Thrombocytopenia. Clinical and Applied Thrombosis/Hemostasis, 2017, 23, 786-792.	1.7	11
53	Realâ€world analysis of haemophilia patients in China: A single centre's experience. Haemophilia, 2020, 26, 584-590.	2.1	10
54	Stromal cell-derived factor-1 rs2297630 polymorphism associated with platelet production and treatment response in Chinese patients with chronic immune thrombocytopenia. Platelets, 2016, 27, 338-343.	2.3	9

#	Article	IF	Citations
55	Decreased TLR4 expression on monocytes may cause regulatory T cells abnormality in patients with primary immune thrombocytopenia. Autoimmunity, 2017, 50, 283-292.	2.6	9
56	Numerical and functional defects in CD8⁺CD28^{â˜'} Tâ€suppressor lymphocytes from patients with primary immune thrombocytopenia. British Journal of Haematology, 2017, 178, 292-301.	2.5	9
57	Long-term efficacy and safety of prophylaxis with recombinant factor VIII in Chinese pediatric patients with hemophilia A: a multi-center, retrospective, non-interventional, phase IV (ReCARE) study. Current Medical Research and Opinion, 2017, 33, 1223-1230.	1.9	9
58	An FcÎ³RIIb transmembrane polymorphism in Chinese ITP patients. Platelets, 2010, 21, 479-485.	2.3	8
59	Retrospective analysis of 1,226 Chinese patients with haemophilia in a single medical centre. Journal of Thrombosis and Thrombolysis, 2014, 38, 92-97.	2.1	8
60	Mutation profiling by targeted sequencing of â€œtripleâ€negativeâ€•essential thrombocythaemia patients. British Journal of Haematology, 2018, 181, 857-860.	2.5	8
61	Reduced PTEN involved in primary immune thrombocytopenia via contributing to B cell hyper-responsiveness. Molecular Immunology, 2018, 93, 144-151.	2.2	8
62	Interleukin-7 is decreased and maybe plays a pro-inflammatory function in primary immune thrombocytopenia. Platelets, 2015, 26, 243-249.	2.3	7
63	Efficacy and safety of prophylaxis with BAY 81â€8973 in Chinese patients with severe haemophilia A enrolled in the LEOPOLD II trial. Haemophilia, 2019, 25, e153-e158.	2.1	7
64	CD70â€silenced dendritic cells induce immune tolerance in immune thrombocytopenia patients. British Journal of Haematology, 2020, 191, 466-475.	2.5	7
65	Patients with haemophilia A with inhibitors in China: a national realâ€world analysis and followâ€up. British Journal of Haematology, 2021, 192, 900-908.	2.5	7
66	Mapping the Haem-A-QoL to the EQ-5D-5L in patients with hemophilia. Quality of Life Research, 2022, 31, 1533-1544.	3.1	7
67	Association of FOXP3 gene polymorphisms with chronic immune thrombocytopenia in a Chinese Han population. International Journal of Laboratory Hematology, 2021, 43, 1104-1109.	1.3	6
68	Pharmacokinetic, efficacy and safety evaluation of Bâ€domainâ€deleted recombinant FVIII (SCT800) for prophylactic treatment in adolescent and adult patients with severe haemophilia A. Haemophilia, 2021, 27, 814-822.	2.1	6
69	Effect of Eltrombopag on Platelet Response and Safety Results in Chinese Adults with Chronic ITP-Primary Result of a Phase III Study. Blood, 2014, 124, 1464-1464.	1.4	6
70	Dose tapering to withdrawal stage and longâ€term efficacy and safety of hetrombopag for the treatment of immune thrombocytopenia: Results from an openâ€label extension study. Journal of Thrombosis and Haemostasis, 2022, 20, 716-728.	3.8	6
71	Effects of the multidrug resistance-1 gene on drug resistance in primary immune thrombocytopenia. Autoimmunity, 2016, 49, 486-495.	2.6	5
72	Increased plasma sCXCL16 levels may have a relationship with Th1/Th2 imbalance in primary immune thrombocytopenia. Cytokine, 2017, 99, 124-131.	3.2	5

#	Article	IF	Citations
73	Absence of Association ofInterleukin-18Gene Polymorphisms with Primary Immune Thrombocytopenia in a Chinese Han Population. DNA and Cell Biology, 2014, 33, 537-542.	1.9	4
74	Management of haemophilia patients in the COVIDâ€•19 pandemic: Experience in Wuhan and Tianjin, two differently affected cities in China. Haemophilia, 2020, 26, 1031-1037.	2.1	4
75	Integrin Î²3 Deficiency Results in Hypertriglyceridemia via Disrupting LPL (Lipoprotein Lipase) Secretion. Arteriosclerosis, Thrombosis, and Vascular Biology, 2020, 40, 1296-1310.	2.4	4
76	The State of Skewed X Chromosome Inactivation is Retained in the Induced Pluripotent Stem Cells from a Female with Hemophilia B. Stem Cells and Development, 2017, 26, 1003-1011.	2.1	3
77	Investigating the Added Value of the EQ-5D-5L With Two Bolt-On Items in Patients With Hemophilia. Frontiers in Medicine, 2021, 8, 707998.	2.6	3
78	Demographics, clinical profile and treatment landscape of patients with haemophilia B in China. Haemophilia, 2022, 28, .	2.1	3
79	A novel SERPINC1 frameshift mutation in two antithrombin deficiency families. International Journal of Laboratory Hematology, 2020, 42, e48-e51.	1.3	2
80	Molecular analysis in 12 factor XI deficiency patients from China: Identification of three novel splicing mutations. Thrombosis Research, 2020, 192, 100-102.	1.7	2
81	Current status of haemophilia inhibitor management in mainland China: a haemophilia treatment centres survey on treatment preferences and realâ€•world clinical practices. British Journal of Haematology, 2021, 194, 750-758.	2.5	2
82	Phase 4 Safety and Efficacy Study of Antihemophilic Factor (Recombinant) in Previously Treated Chinese Patients With Severe/Moderately Severe Hemophilia A. Clinical and Applied Thrombosis/Hemostasis, 2021, 27, 107602962198981.	1.7	2
83	Pharmacokinetics, Safety, and Pharmacodynamics of Romiplostim in Chinese Subjects With Immune Thrombocytopenia: A Phase I/II Trial. Clinical Pharmacology in Drug Development, 2022, 11, 379-387.	1.6	2
84	Healthâ€•related quality of life among adults with haemophilia in China: A comparison with ageâ€•matched general population. Haemophilia, 2022, 28, 776-783.	2.1	2
85	Efficacy, safety and pharmacokinetics of recombinant human coagulation factor VIII (omfiloctocog) Tj ETQq1 1 0.784314 rgBT /Overlock	2.1	2
86	Status and trend analysis of prophylactic usage of recombinant factor VIII in Chinese pediatric patients with hemophilia A: ReCare â€“ a retrospective, phase IV, non-interventional study. Current Medical Research and Opinion, 2017, 33, 1571-1578.	1.9	1
87	Safety and Efficacy of Moroctocog Alfa (AF-CC) in Chinese Patients with Hemophilia A: Results of Two Open-Label Studies . Journal of Blood Medicine, 2020, Volume 11, 439-448.	1.7	1
88	Antithrombin, Protein C, Protein S and Activated Protein C Resistance in the General Healthy Chinese Population: Normal Plasmatic Ranges and Genetic Defects.. Blood, 2007, 110, 3982-3982.	1.4	1
89	Abnormal lipid rafts related ganglioside expression and signaling in T lymphocytes in immune thrombocytopenia patients. Autoimmunity, 2016, 49, 58-68.	2.6	0
90	IP-10 and MCP-1 gene polymorphisms in Chinese patients with chronic immune thrombocytopenia. Autoimmunity, 2019, 52, 235-241.	2.6	0

#	Article	IF	Citations
91	Levels of Soluble CD30 and CD26 and Their Clinical Significance in Patients with Primary Immune Thrombocytopenia. BioMed Research International, 2020, 2020, 1-8.	1.9	0
92	First open-label, single-arm, prospective study of real-world use of FIX replacement therapy in a predominantly pediatric hemophilia B population in China. Medicine (United States), 2021, 100, e26077.	1.0	0
93	Distinct Molecular Abnormalities Underlie Unique Clinical Features of Essential Thrombocythemia in Children. Blood, 2014, 124, 4579-4579.	1.4	0
94	Integrin Î±IIbÎ²3-Mediated Outside-in Signaling: Brake or Amplifier of Platelet Activation?. Blood, 2014, 124, 4161-4161.	1.4	0
95	Inhibitors: Diagnostic challenges, unknowns of inhibitor development, treatment of bleeding and surgery, and insights into diagnosis and treatment in China. Haemophilia, 2022, 28, 111-118.	2.1	0